medigraphic.com

2015, Número S1

<< Anterior Siguiente >>

Rev Mex Anest 2015; 38 (S1)


Factores de riesgo cardiovascular en el paciente geriátrico: prevención primaria y secundaria. Identificación del riesgo perioperatorio

Gómez-Sánchez G, Castellanos-Olivares A

Idioma: Español
Referencias bibliográficas: 75
Paginas: 189-196
Archivo PDF: 177.87 Kb.


FRAGMENTO

Introducción

Se realizó una revisión de los aspectos relacionados con los factores de riesgo, los métodos de valoración y las intervenciones que deben realizarse para la prevención primaria y secundaria de las enfermedades cardiovasculares (ECV).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. The World Health Report. 2002 “Reducing risks and promoting healthy life”. Geneva, World Health Organization, 2002.

  2. NHLBI fact book, fiscal year 2003. Bethesda, Md.: National Heart, Lung, and Blood Institute, February 2004. Disponible en http://www.nhlbi.nih.gov/about/factpdf.htm.

  3. NHLBI morbidity and mortality chartbook, 2002. Bethesda, Md.: National Heart, Lung, and Blood Institute, May 2002.

  4. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ. 2000;612:534-542.

  5. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). JAMA. 2003;289:2560-2572.

  6. Guideliness Commitee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension. 2003;21:1011-1053.

  7. Lloyd-Jones DM. Impact of systolic versus diastolic blood pressure level of JNC-VI blood pressure stage classification. Hypertension. 1999;34:381-385.

  8. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.

  9. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427-1431.

  10. Pini R, Cavallini MC, Bencini F. Cardiac and vascular remodeling in older adults with borderline isolated systolic hypertension: the ICARe dicomano study. Hypertension. 2001;38:1372-1376.

  11. Kostis JB, Davis BR, Cutler J. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. Lancet. 1997;351:1755-1762.

  12. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996;348:1339-1342.

  13. Toth PP. High-density lipoprotein and cardiovascular risk. Circulation. 2004;109:1809-1812.

  14. Dows JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.

  15. LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized control trials. JAMA. 1999;282:2340-2346.

  16. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: metaanalysis of randomized trials. BMJ. 2000;321:983-986.

  17. Long-term intervention with pravastatin in ischemic disease (LIPID) study program. prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med. 1998;339:1349-1357.

  18. Xydakis AM, Ballantyne CM. Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. Curr Opin Cardiol. 2003;18:503-509.

  19. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.

  20. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.

  21. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic hearth disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-1427.

  22. Nissen SE, Tuzcu EM, Schoenhagen P. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.

  23. Cannon CP, Braunwald E, McCabe CH. Comparison of intensive and moderate lipid lowering with statins following acute coronary syndrome. N Engl J Med. 2004;350:1495-1504.

  24. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. 1994;309:901-911.

  25. Humphries SE, Talmud EM, Bolla M, DAY IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358:115-119.

  26. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Eng J Med. 1990;332:213-217.

  27. Wilson K, Gibson N, William A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: metaanalysis of cohort studies. Arch Intern Med. 2000;160:939-944.

  28. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86-97.

  29. Anderson KM, Wilson PWF, Odell PM, Kannel WB. Un update coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-362.

  30. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.

  31. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492.

  32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2496.

  33. British Cardiac Society, British Hyperlipidemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ. 2000;320:705-708.

  34. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709-710.

  35. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomized controlled trials. BMJ. 2001;323:75-81. Ars Pharmaceutica. 2004;45:187-210.

  36. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105:310-315.

  37. Assmann G, Cullen P, Schule H. Risk assessment of myocardial infarction and stroke. International Congress Series. 2004;1262:30-38.

  38. Conroy RM, Pyörälä K, Fitzgerald AP. Estimation of cardiovascular disease in Europe: the ten-year risk of fatal SCORE project. Eur Heart J. 2003;24:987-1003.

  39. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J. Executive summary European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-1610.

  40. Pietinen P, Rimm EB, Korhonen P. Intake of dietary fibre and risk coronary heart disease in a cohort of Finnish men. Circulation. 1999;94:2720-2727.

  41. Knekt P, Reunanen A, Jarvinen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139:1180-1189.

  42. Knekt P, Isotupa S, Rissanen H. Quercetin intake in the incidence of cerebrovascular disease. Eur J Clin Nutr. 2000;54:415-417.

  43. Hu FB, Stampfer MJ, Colditz GA. Physical Activity and Risk of Stroke in Women. JAMA. 2000;283:2961-2967.

  44. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003;34:2475-2482.

  45. Hakim AA, Curb JD, Petrovitch H. Effects of walking on coronary heart disease in elderly men: the honolulu heart program. Circulation. 1999;100:9-13.

  46. Press V, Freestone I, George CF. Physical activity: the evidence of benefit in the prevention of coronary heart disease. Q J Med. 2003;96:245-251.

  47. Tanasescu M, Leitzmann MF, Rimm EB. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288:1994-2000.

  48. Thompson PD, Buchner D, Piña IL. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation. 2003;107:3109-3116.

  49. Higashi Y, Yoshizumi M. Exercise and endothelial function: Role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients. Pharmacology & Therapeutics. 2004;102:87-96.

  50. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on Obesity. Geneva: World Health Organization, 1998.

  51. World Health Organization. Obesity and overweigt. Who Global Strategy on Diet, Physical Activity and Health. Geneva: World Health organization, 2003.

  52. Martorell R. Obesity in the developing world. En: Caballero B, Popkin BM editors. The nutrition transition. Diet and disease in the developing world. San Diego: Academic press, 2002:147-64.

  53. Schoenborn CA, Adams PF, Barnes PM, Vickerie JL, Schiller JS. Health Behaviors of Adults: United States, 1999-2001. National Center for Health Statistics. Vital Health Stat 10(219). 2004:60.

  54. Zhu S, Heshka S, Wang Z, Shen W, Allison DB, Ross R, Heymsfield SB. Combination of BMI and Waist Circumference for Identifying Cardiovascular Risk Factors in Whites. Obesity Research 2004; 12:633-645.

  55. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Eng J Med. 2001;344:3-10.

  56. Appel LJ, Moore TJ, Obarzek E. A clinical trial of the effects of dietary patterns on blood pressure. N Eng J Med. 1997;336:1117-1124.

  57. Whelton PK, Appel LJ, Espelland MA. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of non-pharmacologic intervention in the elderly (TONE). JAMA. 1998;279:839-846.

  58. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure. A critical review of current scientific evidence. Hypertension. 2000;35:858-863.

  59. Moore TJ, Conlin PR, Ard J, Svetkey LP. DASH (Dietary Approaches to Stop Hypertension) Diet is effective treatment for stage 1 isolated systolic hipertension. Hypertension. 2001;38:155-158.

  60. Stevens VJ, Obarzanek E, Cook NR. Long term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase 11. Ann Intern Med. 2001;134:1-11.

  61. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544-549.

  62. Georgiades A, Sherwood A, Gullette ECD. Effects of exercise and weight loss on mental stress–induced cardiovascular responses in individuals with high blood pressure. Hypertension. 2000; 36:171-176.

  63. Vollmer WM, Sacks FM, Ard J. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135:1019-1028.

  64. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2000;35:838-843.

  65. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493-503.

  66. Xin X, He J, Frontini MG. Effects of alcohol reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112-1217.

  67. AHA Guidelines. Evidence-Based Guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693.

  68. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arc Intern Med. 2002;162:2405-2410.

  69. Tanuseputro P, Manuel DG, Leung M, Nguyen K, Johansen H. Canadian cardiovascular outcomes research team. Risk factors for cardiovascular disease in Canada. Can J Cardiol. 2003;19:1249-1259.

  70. The Vestfold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention program in patients with coronary heart disease. J Cardiovasc Risk. 2003;10:429-437.

  71. Gavin JR 3rd, Peterson K, Warren-Boulton E. National Diabetes Education Program. Reducing cardiovascular disease risk in patients with type 2 diabetes: a message from the National Diabetes Education Program. Am Fam Physician. 2003;15:1569-1574.

  72. Ornstein SM, Nieter PJ, Dickerson LM. Hypertension management and control in primary care: a study of 20 patients in 14 states. Pharmacotherapy. 2004;24:500-507.

  73. Chinwong S, Reid F, McGlynn S, Hudson S, Flapan A. The need for pharmaceutical care in the prevention of coronary heart disease: an exploratory study in acute myocardial infarction patients. Pharm World Sci. 2004;26:96-101.

  74. Tsuyuki RT, Olson KL, Dubyk AM, Johnson JA. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: The second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Am J Medicine. 2004;116:130-133.

  75. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management. Arch Intern Med. 2002;162:1149-1155.




2020     |     www.medigraphic.com